PTN240719P2500
- 0.68
- 0.000.00%
Palatin Technologies Newsroom
Palatin Technologies Enters Warrant Inducement Agreement With Institutional Investor To Exercise 3,233,277 Shares Issued In November 2022 And October 2023, Raising $6.1M
Palatin Technologies Enters Warrant Inducement Agreement With Institutional Investor To Exercise 3,233,277 Shares Issued In November 2022 And October 2023, Raising $6.1M
Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds
Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based...
Express News | Palatin Technologies: Potential Phase 3 Clinical Study in Ed Patients Who Do Not Respond to Pde5I Monotherapy to Start in H1 2025
Express News | Palatin Announces the Initiation of a Phase 2 Clinical Study of Bremelanotide Co-Administered With a Pde5I for the Treatment of Erectile Dysfunction (Ed)
Sector Update: Health Care Stocks Ease Late Afternoon
Health care stocks were softer late Wednesday afternoon, with the NYSE Health Care Index decreasing 0.3% and the Health Care Select Sector SPDR Fund (XLV) down 0.1%. The iShares Biotechnology ETF (IBB
Palatin Technologies Starts Phase 2 of Obesity Treatment Study
Palatin Technologies (PTN) said Wednesday it has started a phase 2 clinical trial to assess the safety and efficacy of bremelanotide, a melanocortin 4 receptor agonist, administered alongside tirzepat
H.C. Wainwright Maintains Palatin Technologies(PTN.US) With Buy Rating, Maintains Target Price $17
H.C. Wainwright analyst Joseph Pantginis maintains $Palatin Technologies(PTN.US)$ with a buy rating, and maintains the target price at $17.According to TipRanks data, the analyst has a success rate of
Express News | Palatin Technologies: Additional Studies Under Assessment for Multiple Metabolic Conditions
Express News | Palatin Technologies Inc: Topline Data Expected by End of Calendar Year 2024
Express News | Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity
Palatin Technologies (PTN) Upgraded to Buy: What Does It Mean for the Stock?
Analysts Offer Insights on Healthcare Companies: Palatin Technologies (PTN), Prestige Consumer Healthcare (PBH) and CervoMed (CRVO)
Palatin Technologies Inc (PTN) (Q3 2024) Earnings Call Transcript Highlights: Navigating ...
Q3 2024 Palatin Technologies Inc Earnings Call
Earnings Call Summary | Palatin Technologies(PTN.US) Q3 2024 Earnings Conference
The following is a summary of the Palatin Technologies, Inc. (PTN) Q3 2024 Earnings Call Transcript:Financial Performance:Palatin Technologies reported no product sales in the quarter ended March 31,
Palatin Technologies Shares Are Trading Lower After the Company Reported Worse-than-expected Q3 GAAP EPS Results.
Palatin Technologies Shares Are Trading Lower After the Company Reported Worse-than-expected Q3 GAAP EPS Results.
Analysts Are Bullish on These Healthcare Stocks: AEON Biopharma (AEON), Palatin Technologies (PTN)
Palatin Technologies Q3 24 Earnings Conference Call At 11:00 AM ET
Palatin Technologies | 10-Q: Quarterly report
As Of March 31, 2024, Palatin's Cash, Cash Equivalents And Marketable Securities Were $10M Expected To Provide Cash Runway Into Second Half Of Calendar Year 2024
As Of March 31, 2024, Palatin's Cash, Cash Equivalents And Marketable Securities Were $10M Expected To Provide Cash Runway Into Second Half Of Calendar Year 2024